{"id":32593,"date":"2025-04-28T14:45:49","date_gmt":"2025-04-28T06:45:49","guid":{"rendered":"https:\/\/flcube.com\/?p=32593"},"modified":"2025-04-28T14:45:49","modified_gmt":"2025-04-28T06:45:49","slug":"boehringer-ingelheim-biopharmaceuticals-china-completes-pmda-gmp-inspection-for-japan-market-supply","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=32593","title":{"rendered":"Boehringer Ingelheim Biopharmaceuticals (China) Completes PMDA GMP Inspection for Japan Market Supply"},"content":{"rendered":"\n<p>German pharmaceutical leader Boehringer Ingelheim (BI) announced that its Shanghai-based subsidiary, Boehringer Ingelheim Biopharmaceuticals (China) Ltd., has successfully completed a Good Manufacturing Practice (GMP) inspection by Japan\u2019s Pharmaceuticals and Medical Devices Agency (PMDA). This approval authorizes the Pudong production site to supply innovative biologic therapies to the Japanese market.<\/p>\n\n\n\n<p><strong>Significance of the Approval<\/strong><br>The successful PMDA inspection marks a significant milestone for Boehringer Ingelheim&#8217;s global commercial strategy. With this approval, the company can now expand its existing commercial distribution network, which previously covered China, the U.S., and Europe, to include Japan. This expansion underscores the company&#8217;s commitment to providing high-quality biologics to patients worldwide.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>German pharmaceutical leader Boehringer Ingelheim (BI) announced that its Shanghai-based subsidiary, Boehringer Ingelheim Biopharmaceuticals (China)&#8230;<\/p>\n","protected":false},"author":1,"featured_media":32594,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7],"tags":[390],"class_list":["post-32593","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","tag-boehringer-ingelheim"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Boehringer Ingelheim Biopharmaceuticals (China) Completes PMDA GMP Inspection for Japan Market Supply - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"German pharmaceutical leader Boehringer Ingelheim (BI) announced that its Shanghai-based subsidiary, Boehringer Ingelheim Biopharmaceuticals (China) Ltd., has successfully completed a Good Manufacturing Practice (GMP) inspection by Japan\u2019s Pharmaceuticals and Medical Devices Agency (PMDA). This approval authorizes the Pudong production site to supply innovative biologic therapies to the Japanese market.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=32593\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Boehringer Ingelheim Biopharmaceuticals (China) Completes PMDA GMP Inspection for Japan Market Supply\" \/>\n<meta property=\"og:description\" content=\"German pharmaceutical leader Boehringer Ingelheim (BI) announced that its Shanghai-based subsidiary, Boehringer Ingelheim Biopharmaceuticals (China) Ltd., has successfully completed a Good Manufacturing Practice (GMP) inspection by Japan\u2019s Pharmaceuticals and Medical Devices Agency (PMDA). This approval authorizes the Pudong production site to supply innovative biologic therapies to the Japanese market.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=32593\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-04-28T06:45:49+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/2808.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32593#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32593\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Boehringer Ingelheim Biopharmaceuticals (China) Completes PMDA GMP Inspection for Japan Market Supply\",\"datePublished\":\"2025-04-28T06:45:49+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32593\"},\"wordCount\":124,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32593#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/2808.webp\",\"keywords\":[\"Boehringer Ingelheim\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=32593#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32593\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=32593\",\"name\":\"Boehringer Ingelheim Biopharmaceuticals (China) Completes PMDA GMP Inspection for Japan Market Supply - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32593#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32593#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/2808.webp\",\"datePublished\":\"2025-04-28T06:45:49+00:00\",\"description\":\"German pharmaceutical leader Boehringer Ingelheim (BI) announced that its Shanghai-based subsidiary, Boehringer Ingelheim Biopharmaceuticals (China) Ltd., has successfully completed a Good Manufacturing Practice (GMP) inspection by Japan\u2019s Pharmaceuticals and Medical Devices Agency (PMDA). This approval authorizes the Pudong production site to supply innovative biologic therapies to the Japanese market.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32593#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=32593\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32593#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/2808.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/2808.webp\",\"width\":1080,\"height\":608,\"caption\":\"Boehringer Ingelheim Biopharmaceuticals (China) Completes PMDA GMP Inspection for Japan Market Supply\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32593#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Boehringer Ingelheim Biopharmaceuticals (China) Completes PMDA GMP Inspection for Japan Market Supply\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Boehringer Ingelheim Biopharmaceuticals (China) Completes PMDA GMP Inspection for Japan Market Supply - Insight, China&#039;s Pharmaceutical Industry","description":"German pharmaceutical leader Boehringer Ingelheim (BI) announced that its Shanghai-based subsidiary, Boehringer Ingelheim Biopharmaceuticals (China) Ltd., has successfully completed a Good Manufacturing Practice (GMP) inspection by Japan\u2019s Pharmaceuticals and Medical Devices Agency (PMDA). This approval authorizes the Pudong production site to supply innovative biologic therapies to the Japanese market.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=32593","og_locale":"en_US","og_type":"article","og_title":"Boehringer Ingelheim Biopharmaceuticals (China) Completes PMDA GMP Inspection for Japan Market Supply","og_description":"German pharmaceutical leader Boehringer Ingelheim (BI) announced that its Shanghai-based subsidiary, Boehringer Ingelheim Biopharmaceuticals (China) Ltd., has successfully completed a Good Manufacturing Practice (GMP) inspection by Japan\u2019s Pharmaceuticals and Medical Devices Agency (PMDA). This approval authorizes the Pudong production site to supply innovative biologic therapies to the Japanese market.","og_url":"https:\/\/flcube.com\/?p=32593","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-04-28T06:45:49+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/2808.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=32593#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=32593"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Boehringer Ingelheim Biopharmaceuticals (China) Completes PMDA GMP Inspection for Japan Market Supply","datePublished":"2025-04-28T06:45:49+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=32593"},"wordCount":124,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=32593#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/2808.webp","keywords":["Boehringer Ingelheim"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=32593#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=32593","url":"https:\/\/flcube.com\/?p=32593","name":"Boehringer Ingelheim Biopharmaceuticals (China) Completes PMDA GMP Inspection for Japan Market Supply - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=32593#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=32593#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/2808.webp","datePublished":"2025-04-28T06:45:49+00:00","description":"German pharmaceutical leader Boehringer Ingelheim (BI) announced that its Shanghai-based subsidiary, Boehringer Ingelheim Biopharmaceuticals (China) Ltd., has successfully completed a Good Manufacturing Practice (GMP) inspection by Japan\u2019s Pharmaceuticals and Medical Devices Agency (PMDA). This approval authorizes the Pudong production site to supply innovative biologic therapies to the Japanese market.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=32593#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=32593"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=32593#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/2808.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/2808.webp","width":1080,"height":608,"caption":"Boehringer Ingelheim Biopharmaceuticals (China) Completes PMDA GMP Inspection for Japan Market Supply"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=32593#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Boehringer Ingelheim Biopharmaceuticals (China) Completes PMDA GMP Inspection for Japan Market Supply"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/2808.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/32593","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=32593"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/32593\/revisions"}],"predecessor-version":[{"id":32595,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/32593\/revisions\/32595"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/32594"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=32593"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=32593"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=32593"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}